Compare UAA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAA | INBX |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2005 | 2024 |
| Metric | UAA | INBX |
|---|---|---|
| Price | $4.67 | $98.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 27 | 4 |
| Target Price | $6.27 | ★ $266.67 |
| AVG Volume (30 Days) | ★ 8.0M | 282.4K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,966,370,000.00 | $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $4.13 | $28.16 |
| 52 Week High | $8.15 | $155.29 |
| Indicator | UAA | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 32.64 | 43.08 |
| Support Level | N/A | $96.60 |
| Resistance Level | $5.39 | $106.40 |
| Average True Range (ATR) | 0.18 | 5.75 |
| MACD | -0.01 | -1.44 |
| Stochastic Oscillator | 24.60 | 11.13 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 440 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.